A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer

Official Title

JUNIPER: A Randomized Phase 3 Study of Abemaciclib Plus Best Supportive Care Versus Erlotinib Plus Best Supportive Care in Patients With Stage IV NSCLC With a Detectable KRAS Mutation Who Have Progressed After Platinum-Based Chemotherapy


The main purpose of this study is to evaluate how safe and effective the study drug known as abemaciclib is in participants with lung cancer.

Trial Description

Primary Outcome:

  • Overall Survival (OS)
Secondary Outcome:
  • Proportion of Participants Achieving Either Complete or Partial Response (Overall Response Rate)
  • Progression Free Survival (PFS)
  • Change from Baseline in MD Anderson Symptom Inventory-Lung Cancer (MDASI-LC) Score
  • Pharmacokinetics: Area Under the Concentration Curve (AUC) of Abemaciclib
  • Change from Baseline in European Quality of Life - 5 Dimensions - 5 Level (EQ-5D-5L) Score
  • Resource Utilization: Percentage of Participants Who are Hospitalized

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society